MRI gadolinium-based contrast media

• Verfasst von: Bendszus, Martin [VerfasserIn]
• Verfasst von: Laghi, Andrea [VerfasserIn]
• Verfasst von: Munuera, Josep [VerfasserIn]
• Verfasst von: Tanenbaum, Lawrence N. [VerfasserIn]
• Verfasst von: Taouli, Bachir [VerfasserIn]
• Verfasst von: Thoeny, Harriet C. [VerfasserIn]
• Titel: MRI gadolinium-based contrast media
• Titelzusatz: meeting radiological, clinical, and environmental needs
• Verf.angabe: Martin Bendszus, MD, Andrea Laghi, MD, Josep Munuera, MD, PhD, Lawrence N. Tanenbaum, MD, Bachir Taouli, MD and Harriet C. Thoeny, MD
• Ausgabe: Online version of record before inclusion in an issue
• E-Jahr: 2024
• Jahr: 16 January 2024
• Umfang: 12 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 18.03.2024
• Titel Quelle: Enthalten in: Journal of magnetic resonance imaging
• Ort Quelle: New York, NY : Wiley-Liss, 1991
• Jahr Quelle: 2024
• Band/Heft Quelle: (2024), Seite 1-12
• ISSN Quelle: 1522-2586
• DOI: doi:10.1002/jmri.29181
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: gadolinium-based contrast agents
• Sach-SW: gadopiclenol
• Sach-SW: magnetic resonance imaging
• K10plus-PPN: 1883666791

Abstract

Gadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function. Research is underway to reduce the quantity of gadolinium injected, without compromising image quality and diagnosis. The next generation of GBCAs will enable a reduction in the gadolinium dose administered. Gadopiclenol is the first of this new generation of GBCAs, with high relaxivity, thus having the potential to reduce the gadolinium dose while maintaining good in vivo stability due to its macrocyclic structure. High-stability and high-relaxivity GBCAs will be one of the solutions for reducing the dose of gadolinium to be administered in clinical practice, while the development of new technologies, including optimization of MRI acquisitions, new contrast mechanisms, and artificial intelligence may help reduce the need for GBCAs. Future solutions may involve a combination of next-generation GBCAs and image-processing techniques to optimize diagnosis and treatment planning while minimizing exposure to gadolinium. Level of Evidence 5 Technical Efficacy Stage 3